Although studies support the efficacy of the Foley catheter (FC) as a cervical ripening agent in pregnant women at term with intact membranes, its efficacy has not been well studied in women with premature rupture of membranes (PROM). 
of reversibility, and lower risk of tachysystole and fetal heart rate abnormalities. 3 First described in 1967, the FC has been established as both a safe and effective ripening method for women with intact membranes. 6, 7 The FC has been compared with PG for cervical ripening in women at term with intact membranes. A randomized clinical trial by Oliveira et al 8 compared the use of FC with vaginal misoprostol for cervical ripening and labor induction and concluded that FC was as effective as the PG misoprostol. Another randomized controlled study that compared FC with PG E2 gel for cervical ripening in women with unfavorable cervices at term found that cesarean delivery rates were similar between the groups, and FC was associated with fewer fetal and maternal adverse effects. 9 These studies support the efficacy of FC use as a ripening method in women at term with intact membranes; however, its efficacy has not been well studied in women with premature rupture of membranes (PROM); the optimal management of PROM remains unclear.
Between 3% and 19% of all pregnancies are associated with PROM, including 8% to 10% of pregnancies at term. 10 Of women with PROM at term, approximately 40% will take longer than 24 hours after PROM to enter labor spontaneously. 11 Prolongation of latency for greater than 24 hours has been shown to be associated with an increased incidence of chorioamnionitis and neonatal sepsis. 10, 12 In a large randomized trial in women with PROM at term, outcomes associated with expectant management vs labor induction were evaluated. 11 Results demonstrated that expectant management was associated with a significantly increased incidence of clinical chorioamnionitis, postpartum fever, longer maternal hospital stay, and more infant days spent in the neonatal intensive care unit. 11 With these potential risks, expedient delivery seems to be the optimal management for women with PROM at term. 
Methods
The institutional review board approved this retrospective study of women who underwent induction of labor after PROM at Thomas Jefferson University Hospital (TJUH) and Christiana Care Health System (CCHS). At both institutions, patient information is routinely entered into a computer database at the time of delivery. We used these databases to identify women with PROM who were induced between January 2009 and April 2011.
After potential patients were identified, we reviewed their medical records to identify those who underwent cervical ripening with either FC or misoprostol, and necessary data were abstracted from their medical records.
Women were included if they had singleton gesta- 
Discussion
Ideal characteristics of ripening agents include efficacy in decreasing time to delivery, a positive safety profile, and efficacy in increasing the likelihood of vaginal delivery. Although most patients received oxytocin augmentation after the FC was expelled, the decision to start oxyterm without significant differences in efficacy. found that the 2 are equivalent for cervical ripening. We identified one small pilot study that assessed the efficacy of FC in the setting of PROM; however, the study sample tively at a single institution. The differences observed between groups in terms of marital status and race are likely secondary to demographic differences that exist between patient populations at TJUH and CCHS.
Conclusion
The present study adds to the limited data on the use of the FC, specifically in the setting of PROM. We found that the interval to delivery was decreased with the use of the FC without increasing the incidence of cesarean delivery. We believe the present study can provide useful pilot data on which to base a prospective randomized clinical trial to further assess the use of the FC for cervical ripening in the setting of PROM.
tocin while the catheter was still in place was at the discretion of the physician. As a result, 38 of the 122 patients in the FC group received oxytocin before the FC was out. However, in a randomized controlled trial by
Pettker et al, 15 the addition of oxytocin to FC did not shorten the time to delivery and had no effect on the vaginal delivery rate. There were some limitations to the present study.
Because of the study's retrospective design, we were unable to define chorioamnionitis on the basis of clinical findings of uterine tenderness, foul odor of the amniotic fluid, maternal leukocytosis, and fetal tachycardia. However, as chorioamnionitis is an important consideration when choosing a ripening agent, to include all potential cases of chorioamnionitis, we used a broad definition. 13 Another limitation of the present study was that all women who received FC ripening were at one institution and all women who received misoprostol were at the other institution. When the study first started, we planned to include all women who received mechanical ripening or PG ripening at both institutions. After data were collected, we noted that the 2 institutions preferentially used either FC or misoprostol. Given that institutions tend to have protocols for the management of certain conditions (eg, PROM in patients who are not in labor), we would likely not have been able to perform this study retrospec-
